EUVIMEDEUVIMED entdecken
Crossref

Romosozumab (Evenity)

CDA-AMC

Canadian Journal of Health Technologies · 13.10.2026 · 6 (10)

DOI: 10.51731/cjht.2026.1537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.10.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses romosozumab 105 mg/1.17 mL prefilled syringe for subcutaneous injection. Type of review: Request for Advice Requester: Formulary Working Group Indication under consideration: Osteoporosis

Zitieren

APA

CDA-AMC (2026). Romosozumab (Evenity). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1537

Vancouver

CDA-AMC. Romosozumab (Evenity). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1537

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Romosozumab (Evenity)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {10},
  doi = {10.51731/cjht.2026.1537}
}
Kostenlos starten →